James E. Rothman has been appointed to the newly created position of chief scientific adviser at Amersham. He has served seven years on the company's scientific advisory board. Rothman will work with CEO William Castell and will sit on Amersham's
James E. Rothman has been appointed to the newly created position of chief scientific adviser at Amersham. He has served seven years on the company's scientific advisory board. Rothman will work with CEO William Castell and will sit on Amersham's Portfolio Committee, which has primary responsibility for recommending overall strategic direction of the company's research.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.